Soligenix (SNGX) Competitors

Tempest Therapeutics (NASDAQ:TPST) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.

Which has more risk and volatility, TPST or SNGX?

Tempest Therapeutics has a beta of -2, meaning that its stock price is 300% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Does the media favor TPST or SNGX?

In the previous week, Tempest Therapeutics had 5 more articles in the media than Soligenix. MarketBeat recorded 9 mentions for Tempest Therapeutics and 4 mentions for Soligenix. Soligenix's average media sentiment score of 0.88 beat Tempest Therapeutics' score of 0.46 indicating that Soligenix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Soligenix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in TPST or SNGX?

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 4.7% of Tempest Therapeutics shares are held by company insiders. Comparatively, 3.1% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts rate TPST or SNGX?

Tempest Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 301.61%. Given Tempest Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tempest Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Soligenix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the MarketBeat Community believe in TPST or SNGX?

Soligenix received 176 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 72.97% of users gave Soligenix an outperform vote while only 64.56% of users gave Tempest Therapeutics an outperform vote.

Company	Underperform	Outperform
Tempest Therapeutics	Outperform Votes 102 64.56%	Underperform Votes 56 35.44%
Soligenix	Outperform Votes 278 72.97%	Underperform Votes 103 27.03%

Which has better earnings and valuation, TPST or SNGX?

Soligenix has lower revenue, but higher earnings than Tempest Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$29.49M	-$17.98	-0.42
Soligenix	-$117.03K	-52.71	-$6.14M	-$4.29	-0.44

Is TPST or SNGX more profitable?

Tempest Therapeutics has a net margin of 0.00% compared to Soligenix's net margin of -1,473.38%. Tempest Therapeutics' return on equity of -187.44% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-187.44%	-82.61%
Soligenix	-1,473.38%	-223.29%	-74.18%

Summary

Tempest Therapeutics beats Soligenix on 9 of the 17 factors compared between the two stocks.